

## P & T COMMITTEE MEETING

# Agenda April 7, 2015 1:00 pm – 5:00 p.m.

303 E. 17<sup>th</sup> Ave, 7<sup>th</sup> floor conference room, Denver, Colorado-Please note change in location, please sign in and obtain a badge at the 7<sup>th</sup> floor desk

## **Unfinished Business and General Orders**

- 1. Approval of minutes from the January 6, 2013 P&T Meeting
- 2. Update on Alzheimer's agents
- 3. Update on Atypical Antipsychotics
- 4. Update on Growth Hormones
- 5. Update on Intranasal corticosteroids
- 6. Update on Insulins
- 7. Update on Leukotriene modifiers
- 8. Update on Multiple Sclerosis agents
- 9. Update on Ophthalmic allergy agents
- 10. Update on Sedative/Hypnotics (non-benzodiazepine)
- 11. Update on Statins/Statin combinations

#### **New Business**

## **Global Prior Authorization Discussion**

## **Drug Classes Up for Review:**

- Newer generation antihistamines and antihistamine decongestant combinations
- ➤ Angiotensin receptor blockers and combinations
- > Renin inhibitors and combinations
- > Fibromyalgia agents
- ► Long acting oral opioids
- ➤ Inhaled anticholinergics and combinations
- ➤ Inhaled Beta 2 agonists
- ➤ Long acting inhaled Beta 2 agonists
- > Inhaled corticosteroids and combinations
- > Skeletal muscle relaxants
- > Testosterone Products
- > Topical immunmodulators

### **Each Review will contain:**

Drug class Overview and Agents up for review for each Drug Class

- > Oral presentation by manufacturers, providers, and public following overview
- ➤ Committee Discussion and Recommendations for each Class

**Upcoming Meeting Date**: Tuesday, July 7<sup>th</sup> or 14th, 2015; 1:00 p.m. – 5:00 p.m. location TBD.

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Swaniee Grubb at 303-866-3614 or by email at <a href="mailto:Swaniee.grubb@state.co.us">Swaniee.grubb@state.co.us</a>. Written public comments can be submitted to <a href="mailto:pdlproject@state.co.us">pdlproject@state.co.us</a> and will be distributed to all present P&T Committee Members.